Biotricity Inc. (BTCY)

NASDAQ: BTCY · IEX Real-Time Price · USD
1.11
-0.02 (-1.77%)
Aug 18, 2022 3:55 PM EDT - Market closed
-1.77%
Market Cap 57.61M
Revenue (ttm) 7.27M
Net Income (ttm) -29.35M
Shares Out 51.90M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,127
Open 1.14
Previous Close 1.13
Day's Range 1.09 - 1.14
52-Week Range 0.95 - 5.30
Beta 1.71
Analysts Buy
Price Target 2.55 (+129.7%)
Earnings Date Aug 15, 2022

About BTCY

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood ... [Read more...]

Industry Medical Devices
Employees 44
Stock Exchange NASDAQ
Ticker Symbol BTCY
Full Company Profile

Financial Performance

In 2021, Biotricity's revenue was $7.65 million, an increase of 126.02% compared to the previous year's $3.38 million. Losses were -$29.13 million, 88.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for BTCY stock is "Buy." The 12-month stock price forecast is 2.55, which is an increase of 129.73% from the latest price.

Price Target
$2.55
(129.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biotricity Reports Financial Results for Fiscal 2023 First Quarter

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its fina...

Biotricity to Host Fiscal First Quarter 2023 Financial Results Conference Call on August 15th at 4:30 p.m. ET

REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 /bbBiotricity Inc. (NYSE:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will ho...

Biotricity Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year

Company Reports Record Revenue and Improved Margins REDWOOD CITY, CA / ACCESSWIRE / July 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healt...

Biotricity to Join Russell Microcap(R) Index

REDWOOD CITY, CA / ACCESSWIRE / June 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that the C...

Biotricity to Present at the 2022 H.C. Wainwright Global Investment Conference on Tuesday May 24th

REDWOOD CITY, CA / ACCESSWIRE / May 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is scheduled to present and...

Biotricity Issues Shareholder Update

Company highlights recent achievements and strategic initiatives setting the foundation to drive revenue growth to record levels in calendar 2022 National sales force growing, now covers 27 states for i...

Biotricity to Launch Commercial Sales of Its Disruptive Cardiac Monitoring Device, Biotres in April 2022

Company reports pre-order sales from existing customers of its wireless wearable device for early detection of cardiac arrhythmias REDWOOD CITY, CA / ACCESSWIRE / March 22, 2022 / Biotricity, Inc. (NASD...

Biotricity Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022

Leader in early-detection cardiac diagnostics monitoring solutions joins the ranks of Canva, Microsoft, SpaceX, and more REDWOOD CITY, CA / ACCESSWIRE / March 8, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("...

Biotricity, Inc. to Attend 34th Annual Roth Conference March 13th-15th

Follows fiscal third quarter earnings that saw revenue up 93% year-over-year and Company's highest-ever quarterly cash position Biotricity now taking preorders for Biotres, an FDA-cleared, wireless, wea...

Biotricity Now Taking Pre-Orders for its Biotres Wireless Wearable Cardiac Monitoring Device

Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 REDWOOD CITY, CA / ACCESSWIRE / February 23, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity...

Biotricity Releases Fiscal 2022 Third Quarter Financial Results

Management to host investor call on Tuesday February 15th at 4:15 pm ET 93% YOY Revenue Gains to $1.93 Million Revenue Outpaces SG&A Increase by 2.2x Cash Position of $16.8 Million at Quarter End Is Hig...

Biotricity to Report Third Quarter Fiscal 2022 Financial Results on February 14, 2022

Management to host call on Tuesday, February 15th at 4:15pm ET Sees Calendar-2022 as a breakout year with commercial launch of Bioheart and FDA clearance for Biotres REDWOOD CITY, CA / ACCESSWIRE / Febr...

Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device

Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion -dollar holter market REDWOOD CITY, CA / ACCESSWIRE / January 24, 2022...

Biotricity Expands Distribution of New Bioheart Device on Amazon.com

New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone Now Easy to Buy and Use: No Prescription Needed for Advanced Heart and Lifestyle Solution REDWOOD CI...

Biotricity Completes $12 Million Non-Dilutive Debt Financing

Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms 5-year term deal strengthens balance sheet, positions company for multip...

Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter

The Company believes that it is "well-positioned for 2022." Letter highlights milestones, products roadmap, growth strategy and 2022 goals REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, ...

Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Biotricity Delivers Bioheart: A Groundbreaking Consumer Heart Monitor for Smartphones

Biotricity Releases Fiscal 2022 Second Quarter Financial Results

Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth Strongest balance sheet since inception REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 / Biotricity Inc. (NASDAQ...

Biotricity to Report Second Quarter Fiscal 2022 Financial Results on November 4, 2021

Management to Host Conference Call and Live Webcast at 5pm ET REDWOOD CITY, CA / ACCESSWIRE / November 2, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology c...

Biotricity to Discuss its Breakthrough Patient Monitoring Solutions at Virtual LD Micro Main Event XIV on Oct. 13th

REDWOOD CITY, CA / ACCESSWIRE / October 12, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that i...

Biotricity Launches Biocare Cardiac Application for Samsung's Galaxy Watch4 Series

REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Biotricity Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Biocare Cardiac...

Biotricity Launches Cardiac Application For Samsung's Watch4 Series

Biotricity Inc (NASDAQ:BTCY) announced the upcoming release of the Biocare Cardiac application to be used with Samsung's Galaxy Watch4 series. Biocare is a personal cardiac health application for indivi...

Remote Medical Diagnostic Company, Biotricity, to Ring the Nasdaq Stock Market Opening Bell on Thursday, October 7th

Founder and CEO Waqaas Al Siddiq and Members of Biotricity Management Team to Attend Opening Bell Ceremony on Thursday, October 7, 2021 at 9:30am E.T. REDWOOD CITY, CA / ACCESSWIRE / October 6, 2021 / B...

Biotricity to Discuss Expansion of Remote Monitoring Medical Device Products at Oppenheimer Fall Healthcare Life Scie...

Biokit is the Expansion of the Company's Bioflux Cardiac-Diagnostic Offering Kits on Track for Launch in Early 2022 REDWOOD CITY, CA / ACCESSWIRE / September 21, 2021 / Biotricity Inc. (NASDAQ:BTCY), a ...

Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health...

Biotricity (NASDAQ: BTCY) is reforming the healthcare market as one of the fastest-growing companies in medtech. The company bridges the gap in remote cardiac monitoring, preventive and chronic care man...